Naruo Yoshimura

Prof. Dr. Naruo Yoshimura

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2006 in Lung Cancer
Verified
Journal Article
Closed access
NYNaruo Yoshimura
Naruo Yoshimura
SKShinzoh Kudoh
Shinzoh Kudoh
TKTatsuo Kimura
Tatsuo Kimura
SMShigeki Mitsuoka
Shigeki Mitsuoka
KMKuniomi Matsuura
Kuniomi Matsuura
MFMasahiro Fukuoka
Masahiro Fukuoka

1 October 2015 in Lung Cancer
Verified
Journal Article
Closed access
NYNaruo Yoshimura
Naruo Yoshimura
SKShinzoh Kudoh
Shinzoh Kudoh
SMShigeki Mitsuoka
Shigeki Mitsuoka
NYNaoki Yoshimoto
Naoki Yoshimoto
TOTakako Oka
Takako Oka
KHKazuto Hirata
Kazuto Hirata

1 January 2013 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
NYNaruo Yoshimura
Naruo Yoshimura
KOKyoichi Okishio
Kyoichi Okishio
SMShigeki Mitsuoka
Shigeki Mitsuoka
TKTatsuo Kimura
Tatsuo Kimura
TKTomoya Kawaguchi
Tomoya Kawaguchi
SKShinzoh Kudoh
Shinzoh Kudoh
Patients with epidermal growth factor receptor (EGFR) mutation positive non-small-cell lung cancer exhibited marked response to gefitinib or erlotinib. In most cases, however, the patients showed disease progression after EGFR-tyrosine kinase inhibitor (TKI) treatment. We evaluated the efficacy and safety of pemetrexed in combination with EGFR-TKI in patients with disease progression. Patients with EGFR-mutant stage IIIB or IV non-small-cell lung cancer that progressed during gefitinib or erlotinib therapy were administered pemetrexed with the continuation of EGFR-TKI treatment. Pemetrexed was administered on day 1 at a dose of 500 mg/m, and EGFR-TKI was sequentially administered on days 2 to 16. This treatment was repeated every 3 weeks until disease progression. The primary endpoint was disease control rate. Twenty-seven patients were enrolled in this study. The median number of treatment cycles was six. Overall response rate was 25.9% (95% confidence interval, 9.4%-42.4%) and disease control rate was 77.8% (95% confidence interval, 62.1%-93.5%). Grade 3/4 hematological toxicities were neutropenia (22.2%), leukopenia (14.8%), and anemia (7.4%). Grade 4 nonhematological toxicities were not observed. Major grade 3 nonhematological toxicities were anorexia (14.8%), infection (14.8%), and fatigue (11.1%). The median progression-free survival was 7.0 months, and median survival time was 11.4 months. No treatment-related deaths occurred. Pemetrexed in combination with erlotinib or gefitinib after disease progression shows favorable response and acceptable toxicity.

4 December 2014 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
TOTakako Oka
Takako Oka
TKTatsuo Kimura
Tatsuo Kimura
TSTomohiro Suzumura
Tomohiro Suzumura
NYNaoki Yoshimoto
Naoki Yoshimoto
TNToshiyuki Nakai
Toshiyuki Nakai
KHKazuto Hirata
Kazuto Hirata
Renal toxicity is a clinical problem that affects 28 − 42% of patients undergoing treatment with cisplatin. Renal toxicity can be minimized by high volume hydration with mannitol diuresis. Recent reports have shown that cisplatin induces depletion of Mg and that Mg supplementation can reduce renal toxicity. We hypothesized that Mg infusion combined with low volume hydration may not be sufficient to overcome cisplatin-induced renal toxicity. In total, 85 patients with lung cancer receiving their first cycle of cisplatin-based chemotherapy at the Osaka City University Hospital were classified into three groups: those administered high volume hydration without Mg infusion (high-volume Mg-), high volume hydration with Mg infusion (high-volume Mg+), and with low volume hydration with Mg infusion (low-volume Mg+). Serum creatinine (sCr) and creatinine clearance (CrCl) were examined before and after treatment with cisplatin. Multivariable analysis was carried out to identify the most important contributing factors. There were no significant differences in pre-treatment sCr levels or CrCl between groups. In the high-volume Mg- group, post-treatment sCr significantly increased compared with pre-treatment levels, while post-CrCl significantly decreased compared with pre-treatment CrCl (p < 0.001 and p < 0.001, respectively). In the high-volume Mg+ group, there was no significant difference between pre- and post-treatment levels of sCr, or between pre- and post-treatment CrCl (p = 0.118 and p = 0.254, respectively). In the low-volume Mg+ group, there was a trend towards increased sCr levels and decreased CrCl after treatment (p = 0.068 and p = 0.055, respectively). Multivariate analysis revealed that the absence of Mg infusion and low-volume hydration were both independent factors for decreased CrCl (p < 0.001 and p = 0.001, respectively). High-volume hydration and Mg infusion reduces the renal toxicity induced by cisplatin. A low-volume Mg+ regimen may be considered for patients with adequate renal function. Trial Registration: Observational Study UMIN000013950; Registered 13 May 2014

4 December 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TSTomohiro Suzumura
Tomohiro Suzumura
TKTatsuo Kimura
Tatsuo Kimura
SKShinzoh Kudoh
Shinzoh Kudoh
KUKanako Umekawa
Kanako Umekawa
MNMisato Nagata
Misato Nagata
KHKazuto Hirata
Kazuto Hirata
Background: Rash, liver dysfunction, and diarrhea are known major adverse events associated with erlotinib and gefitinib. However, clinical trials with gefitinib have reported different proportions of adverse events compared to trials with erlotinib. In anin vitrostudy, cytochrome P450 (CYP) 2D6 was shown to be involved in the metabolism of gefitinib but not erlotinib. It has been hypothesized that CYP2D6 phenotypes may be implicated in different adverse events associated with gefitinib and erlotinib therapies.Methods: The frequency of each adverse event was evaluated during the period in which the patients received gefitinib or erlotinib therapy. CYP2D6 phenotypes were determined by analysis ofCYP2D6genotypes using real-time polymerase chain reaction techniques, which can detect single-nucleotide polymorphisms. The CYP2D6 phenotypes were categorized into 2 groups according to functional or reduced metabolic levels. In addition, we evaluated the odds ratio (OR) of the adverse events associated with each factor, including CYP2D6 activities and treatment types.Results: A total of 232 patients received gefitinib therapy, and 86 received erlotinib therapy. Reduced function of CYP2D6 was associated with an increased risk of rash of grade 2 or more (OR, 0.44; 95% confidence interval [CI], 0.21–0.94;*p= 0.03), but not diarrhea ≥ grade 2 (OR, 0.49; 95% CI, 0.17–1.51;*p= 0.20) or liver dysfunction ≥ grade 2 (OR, 1.08; 95% CI, 0.52–2.34;*p= 0.84) in the gefitinib cohort. No associations were observed between any adverse events in the erlotinib cohort and CYP2D6 phenotypes (rash: OR, 1.77; 95% CI, 0.54–6.41;*p= 0.35/diarrhea: OR, 1.08; 95% CI, 0.21–7.43;*p= 0.93/liver dysfunction: OR, 0.93; 95% CI, 0.20–5.07;*p= 0.93).Conclusions: The frequency of rash was significantly higher in patients with reduced CYP2D6 activity who treated with gefitinib compared to patients with functional CYP2D6. CYP2D6 phenotypes are a risk factor for the development of rash in response to gefitinib therapy.

8 April 2013 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
KUKanako Umekawa
Kanako Umekawa
TKTatsuo Kimura
Tatsuo Kimura
SKShinzoh Kudoh
Shinzoh Kudoh
TSTomohiro Suzumura
Tomohiro Suzumura
TOTakako Oka
Takako Oka
KHKazuto Hirata
Kazuto Hirata
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), routinely used to treat advanced non-small-cell lung cancer (NSCLC) patients with activated EGFR mutations, are associated with excellent response and improved performance status. Recently, pro-inflammatory cytokines, such as regulated upon activation normal T cell expressed and secreted (RANTES), interleukin (IL)-10 and IL-8 have been proposed as mediators of cancer development. EGFR-TKIs have been found to affect this network of pro-inflammatory cytokines. Methods: EGFR-TKIs (erlotinib, 150 mg/day; and gefitinib, 250 mg/day) were administered once per day. Treatment was continued until disease progressed or the patient developed intolerable symptoms of toxicity, or withdrew his/her consent for study participation. The treatment was a part of standard care. We investigated the correlation between plasma pro-inflammatory cytokines (including plasma RANTES, IL-10, and IL-8) levels and clinical outcomes following EGFR-TKI treatment in lung cancer patients. Pro-inflammatory cytokine levels were evaluated at diagnosis and on treatment day 30 after the first administration of EGFR-TKIs. Results: Overall, 33 patients were enrolled. Plasma pro-inflammatory cytokine levels were determined for all patients at diagnosis. Plasma samples from 26 patients were obtained on treatment day 30. High level of RANTES at diagnosis was associated with severe general fatigue (P = .026). Low level of RANTES at diagnosis was significantly associated with long-term survival (P = .0032). Percent decrease change of IL-10 was associated with severity of rash (P = .037). The plasma IL-8 level on treatment day 30 (median, 5.48 pg/mL; range, 0.49–26.13 pg/mL) was significantly lower than the level at diagnosis (median 10.45 pg/mL; 3.04–54.86 pg/mL; P = .021). Conclusions: These results suggest that EGFR-TKIs may suppress systemic inflammation and promote tumor shrinkage. The network of pro-inflammatory cytokines was affected by EGFR-TKI treatment for NSCLC. In addition, the clinical outcomes of EGFR-TKI treatment were influenced by the status of the plasma pro-inflammatory cytokines at diagnosis.